Suppr超能文献

孕早期暴露于阿莫西林/克拉维酸:一项前瞻性对照研究。

First-trimester exposure to amoxycillin/clavulanic acid: a prospective, controlled study.

作者信息

Berkovitch Matitiahu, Diav-Citrin Orna, Greenberg Revital, Cohen Michal, Bulkowstein Mordechai, Shechtman Svetlana, Bortnik Oxana, Arnon Judy, Ornoy Asher

机构信息

Clinical Pharmacology and Toxicology unit, Drug Consultation Centre, Assaf Harofeh Medical Centre, Zerifin, Israel.

出版信息

Br J Clin Pharmacol. 2004 Sep;58(3):298-302. doi: 10.1111/j.1365-2125.2004.02138.x.

Abstract

AIMS

The number of published studies on the use of amoxycillin/clavulanic acid during pregnancy is small and so is the number of pregnancies investigated in those studies. In this study we wished to investigate prospectively the safety of intrauterine exposure to amoxycillin/clavulanic acid in a relatively large cohort of women.

METHODS

Women treated (n = 191) with amoxycillin/clavulanic acid during the first trimester of pregnancy were recruited from two teratogen information centres in Israel. Exposed women were matched for age, smoking habits and alcohol consumption with 191 controls exposed to amoxycillin only for similar medical indications.

RESULTS

Maternal age, birth weight, gestational age at delivery, rates of live births and abortions were comparable between the two groups. Rates of major malformations in the amoxycillin/clavulanic acid group (3/158, 1.9%) did not differ significantly from controls (5/163, 3%) (P = 0.49, relative risk = 0.62, 95% confidence interval 0.15, 2.55), and were within the expected baseline risk for the general population.

CONCLUSION

These data suggest that exposure to amoxycillin/clavulanic acid during pregnancy is unlikely to be associated with an increased risk of malformations.

摘要

目的

关于孕期使用阿莫西林/克拉维酸的已发表研究数量较少,且这些研究中所调查的妊娠案例数量也不多。在本研究中,我们希望前瞻性地调查相对大量女性群体宫内暴露于阿莫西林/克拉维酸的安全性。

方法

从以色列的两个致畸物信息中心招募在妊娠早期接受阿莫西林/克拉维酸治疗的女性(n = 191)。将暴露组女性与191名因类似医学指征仅暴露于阿莫西林的对照组女性在年龄、吸烟习惯和饮酒量方面进行匹配。

结果

两组之间的产妇年龄、出生体重、分娩时的孕周、活产率和流产率相当。阿莫西林/克拉维酸组的主要畸形率(3/158,1.9%)与对照组(5/163,3%)相比无显著差异(P = 0.49,相对风险 = 0.62,95%置信区间0.15,2.55),且在一般人群预期的基线风险范围内。

结论

这些数据表明孕期暴露于阿莫西林/克拉维酸不太可能与畸形风险增加相关。

相似文献

1
First-trimester exposure to amoxycillin/clavulanic acid: a prospective, controlled study.
Br J Clin Pharmacol. 2004 Sep;58(3):298-302. doi: 10.1111/j.1365-2125.2004.02138.x.
2
Pregnancy outcome of women inadvertently exposed to ribostamycin during early pregnancy: a prospective cohort study.
Reprod Toxicol. 2009 Apr;27(2):196-8. doi: 10.1016/j.reprotox.2008.12.008. Epub 2008 Dec 31.
3
Metamizol (dipyrone, optalgin) in pregnancy, is it safe? A prospective comparative study.
Eur J Obstet Gynecol Reprod Biol. 2005 Apr 1;119(2):176-9. doi: 10.1016/j.ejogrb.2004.07.004.
4
A prospective controlled multicentre study of clarithromycin in pregnancy.
Am J Perinatol. 1998;15(9):523-5. doi: 10.1055/s-2007-994053.
5
Pregnancy outcome after in utero exposure to itraconazole: a prospective cohort study.
Am J Obstet Gynecol. 2000 Sep;183(3):617-20. doi: 10.1067/mob.2000.105962.
7
Pregnancy outcome after gestational exposure to the new macrolides: a prospective multi-center observational study.
Eur J Obstet Gynecol Reprod Biol. 2008 Nov;141(1):31-4. doi: 10.1016/j.ejogrb.2008.07.008. Epub 2008 Aug 29.
9
The safety of amoxicillin and clavulanic acid use during the first trimester of pregnancy.
Br J Clin Pharmacol. 2019 Dec;85(12):2856-2863. doi: 10.1111/bcp.14118. Epub 2019 Dec 3.

引用本文的文献

1
A Guide to the Management of Hidradenitis Suppurativa in Pregnancy and Lactation.
Am J Clin Dermatol. 2025 May;26(3):345-360. doi: 10.1007/s40257-025-00935-x. Epub 2025 Mar 25.
2
The safety of amoxicillin and clavulanic acid use during the first trimester of pregnancy.
Br J Clin Pharmacol. 2019 Dec;85(12):2856-2863. doi: 10.1111/bcp.14118. Epub 2019 Dec 3.
3
Pregnancy and inflammatory bowel diseases: Current perspectives, risks and patient management.
World J Gastrointest Pharmacol Ther. 2015 Nov 6;6(4):156-71. doi: 10.4292/wjgpt.v6.i4.156.
4
Prophylaxis and treatment of anthrax in pregnant women.
Obstet Gynecol. 2013 Oct;122(4):885-900. doi: 10.1097/AOG.0b013e3182a5fdfd.
5
Management of inflammatory bowel disease in the pregnant patient.
World J Gastroenterol. 2008 Mar 7;14(9):1326-32. doi: 10.3748/wjg.14.1326.
6
Treating common problems of the nose and throat in pregnancy: what is safe?
Eur Arch Otorhinolaryngol. 2008 May;265(5):499-508. doi: 10.1007/s00405-008-0601-4. Epub 2008 Feb 12.
7
Treating common ear problems in pregnancy: what is safe?
Eur Arch Otorhinolaryngol. 2008 Feb;265(2):139-45. doi: 10.1007/s00405-007-0534-3. Epub 2007 Nov 23.
8
Fertility and pregnancy in the patient with inflammatory bowel disease.
Gut. 2006 Aug;55(8):1198-206. doi: 10.1136/gut.2005.078097.

本文引用的文献

1
Augmentin treatment during pregnancy and the prevalence of congenital abnormalities: a population-based case-control teratologic study.
Eur J Obstet Gynecol Reprod Biol. 2001 Aug;97(2):188-92. doi: 10.1016/s0301-2115(00)00545-5.
2
The teratogenicity of anticonvulsant drugs.
N Engl J Med. 2001 Apr 12;344(15):1132-8. doi: 10.1056/NEJM200104123441504.
4
A practical look at the clinical usefulness of the beta-lactam/beta-lactamase inhibitor combinations.
Ann Pharmacother. 1996 Oct;30(10):1130-40. doi: 10.1177/106002809603001013.
6
In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin.
J Antimicrob Chemother. 1980 Jul;6(4):455-70. doi: 10.1093/jac/6.4.455.
8
Comparative study of amoxicillin-clavulanic acid and cephalexin in the treatment of bacteriuria during pregnancy.
Antimicrob Agents Chemother. 1985 Apr;27(4):508-10. doi: 10.1128/AAC.27.4.508.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验